Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMORFZD)

Drug Name

Tolamba Drug Info

Synonyms

AIC, Dynavax; AIC, UCB Pharma; AIC-0003; Allergy therapeutic, Dynavax; Amb a 1 ISS conjugate, Dynavax; Ragweed allergy vaccine, Dynavax; Ragweed allergy vaccine, UCB Pharma; ISS-1018 (allergy), Dynavax

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMORFZD

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Toll-like receptor 9 (TLR9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[3]
SD-101	DMAMTGI	Hepatitis C virus infection	1E51.1	Phase 3	[4]
MGN-1703	DMCJRL1	Colorectal cancer	2B91.Z	Phase 3	[5]
IMO-2125	DM735FA	Melanoma	2C30	Phase 3	[6]
Tilsotolimod	DMGYK2N	Melanoma	2C30	Phase 3	[7]
MIS-416	DM7K4YR	Autoimmune diabetes	5A10	Phase 2	[8]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[9]
BL-7040	DMSBPJI	Inflammatory bowel disease	DD72	Phase 2	[10]
CYT003	DM4LJH8	Asthma	CA23	Phase 2	[11]
CpG-10101	DM6MUCX	Hepatitis C virus infection	1E51.1	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 9 (TLR9)	TTSHG0T	TLR9_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00537355) An Evaluation of the Efficacy and Safety of TOLAMBA for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber. U.S. National Institutes of Health.
2	Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291.
3	Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
4	Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
5	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
6	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
7	Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
8	DOI: 10.1371/journal.pone.0087712
9	Company report (Iderapharma)
10	Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
11	CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
12	Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.